The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

(JAMA Network Open) Real-world data showed that low-risk patients who underwent transcatheter aortic valve replacement (TAVR) ...

Solo Pace announced today that it received FDA clearance for its SoloPace Control System for temporary pacing in TAVR ...

CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal of ...

Solo Pace Incorporated, an emerging medical technology company, announced both FDA Clearance and First-In-Human use of their SoloPace Control System for temporary pacing in Transcatheter Aortic Valve ...

Pitted against more established balloon-expandable Sapien 3 valves in TAVR for severe aortic stenosis, the Myval devices ...

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system exceeded safety and performance goals, according to results of the ALIGN-AR ...

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions against an 'irrational' rush to move to younger patients ahead of the data.

The U.S. Medicare draft inpatient rule for fiscal 2026 discusses a number of coding proposals, although the agency seems disinclined to go along with a proposal to increase payment rates for TAVR ...

With surveillance, conversion to acute valve syndrome happened frequently and was linked to worse clinical outcomes.

At 5 years, there was no difference in death or disabling stroke between transcatheter aortic valve replacement and surgery in patients at low surgical risk. Both groups had improvements in ...

Medtronic, Abbott and Boston Scientific had updates on their devices used in heart valve disease treatment at the event.